Acquisition · Biotech (migraine drug)
SNBL buys Nasdaq-listed migraine drug developer Satsuma for $0.91 a share plus a payout right
- Buyer
- Shin Nippon Biomedical Laboratories (SNBL) (Kagoshima)
- Target
- Satsuma Pharmaceuticals, South San Francisco, California
- Value
- $0.91 a share in cash plus a right to up to $5.77 more; about ¥3.86B (about $28M) paid
- Status
- Tender offer completed; Satsuma became a subsidiary June 8, 2023.
- Date
- 2023-04-17
Shin Nippon Biomedical Laboratories, a Japanese drug-testing company that owned 8.4% of Satsuma, agreed to buy the rest through a tender offer at $0.91 a share in cash plus a contingent value right worth up to $5.77 a share if Satsuma's nasal migraine powder STS101 earns money later. SNBL put the cash cost at about ¥3.86 billion. STS101 uses SNBL's own nasal delivery technology and had been filed with the FDA in March 2023.
Why it matters
SNBL gets worldwide rights to a drug built on its own technology. The CVR shifts some of the risk to former shareholders, a common tool when a small biotech is sold before approval.
What happened to the drug
The FDA first turned down STS101 over manufacturing and quality data, without asking for new clinical trials. After Satsuma and SNBL resubmitted, the FDA approved it as Atzumi on April 30, 2025, the first nasal powder form of the migraine drug dihydroergotamine. Approval was a key step toward the payments promised under the contingent value right.
About Satsuma
Satsuma was founded in 2016 and listed on Nasdaq in September 2019. It built STS101 on SNBL's own nasal delivery platform and had finished Phase 3 trials before the deal. Owning Satsuma gave SNBL exclusive worldwide rights to develop, make and sell the drug.
Sources
Kakehashi M&A News home
